Literature DB >> 25062075

Adherence to multiple medications prescribed for a chronic disease: a methodological investigation.

Ramsankar Basak1, David J McCaffrey Iii, John P Bentley, Sarahmona M Przybyla, Donna West-Strum, Benjamin F Banahan.   

Abstract

BACKGROUND: Many patients receive multiple medications for the treatment of a disease. While monitoring adherence is important, a composite measure of adherence is useful for estimating adherence to multiple medications in these patients. There are multiple ways to compute composite estimates of adherence to multiple medications, including (a) 80% of days covered by at least 1 medication ("at least 1"); (b) 80% of days covered by both medications ("both"); (c) 80% of days covered by each medication measured separately ("all"); and (d) computing an average of the individual medication adherence estimates ("average"). Comparison of adherence rates to individual medications and that of composite estimates are important for intervention decisions and effective disease management.
OBJECTIVES: To (a) examine adherence to multiple medications prescribed for a disease; (b) estimate composite adherence to multiple medications prescribed for a disease; and (c) determine the rate of differential classification of a patient being adherent as is estimated by different available algorithms.
METHODS: A retrospective cohort study was designed using 2002-2003 MarketScan Commercial Claims and Encounters data. To be included in the cohort, patients had to be less than aged 65 years and had to have separate prescriptions filled for 2 classes of diabetes medications (i.e., any sulfonylurea [SU] and any thiazolidinedione [TZD]) at least once; patients taking other diabetic medications over the observation period were excluded. Adherence was measured by proportion of days covered (PDC) over periods of 90 days (8 quarters total) and cumulatively over the 2-year study period. For some composite adherence estimates, patients were considered adherent if PDC ≥ 80%. Survival curves using the life-table method were constructed to compare the time until PDC became less than  80% as estimated by the 3 different categorical composite measures.
RESULTS: A total of 6,043 patients were included in the analysis. Across the 8 quarters under consideration, the average PDC estimates ranged between 69.8%-84.2% for SUs and 70.3%-85.6% for TZDs. The mean composite PDC based on the average algorithm varied between 69.4% and 84.9% when measured over each quarter or cumulatively. Similarly, the rates of composite adherence ranged from 74.5% to 88.2%, 46.4% to 61.2%, and 47.7% to 62.9% for the "at least 1," "both," and "all" methods, respectively. Many subjects were classified as adherent by 1 composite dichotomous measure but not by all 3 dichotomous measures (i.e., "all," "at least 1," and "both"); of these patients, 30.6%-38.2% were classified differently as to their adherence status over different quarters by different measures. Survival curves of categorical composite measures were different (P  less than  0.05) from one another. "At least 1" identified more patients as persistent and showed a much slower decline than did the "all" or "both" approaches.
CONCLUSIONS: Subjects were found to have a level of adherence-as estimated by individual medication adherence and composite adherence metrics-for multiple medications prescribed for a disease that, while not optimal from the perspective of patient care, was not entirely poor. In addition, composite estimates of adherence considerably varied depending on algorithms used. Most importantly, a large number of patients appeared to be subject to inconsistent classification based on adherence measurement algorithm. Adherence estimates produced by different composite measurement approaches give rise to difficulty in consistent interpretation, which may be detrimental to appropriate patient care decision making.

Entities:  

Mesh:

Year:  2014        PMID: 25062075     DOI: 10.18553/jmcp.2014.20.8.815

Source DB:  PubMed          Journal:  J Manag Care Spec Pharm


  7 in total

1.  Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?

Authors:  Khedidja Hedna; Katja M Hakkarainen; Hanna Gyllensten; Anna K Jönsson; Karolina Andersson Sundell; Max Petzold; Staffan Hägg
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

2.  Antihypertensive Medication Adherence and Risk of Cardiovascular Disease Among Older Adults: A Population-Based Cohort Study.

Authors:  Quanhe Yang; Anping Chang; Matthew D Ritchey; Fleetwood Loustalot
Journal:  J Am Heart Assoc       Date:  2017-06-24       Impact factor: 5.501

3.  Impact of late-to-refill reminder calls on medication adherence in the Medicare Part D population: evaluation of a randomized controlled study.

Authors:  Michael S Taitel; Ying Mu; Angshuman Gooptu; Youbei Lou
Journal:  Patient Prefer Adherence       Date:  2017-02-28       Impact factor: 2.711

4.  Evaluating Glycemic Control in Patients with Type 2 Diabetes Suboptimally Controlled on Basal Insulin: UK ATTAIN Real-World Study.

Authors:  Edward B Jude; Mark Nixon; Caroline O'Leary; Melissa Myland; Nick Gooch; Alka Shaunik; Elisheva Lew
Journal:  Diabetes Ther       Date:  2019-07-18       Impact factor: 2.945

5.  Evaluating glycaemic control in patients poorly controlled on oral antidiabetic drugs in real-world setting: Results from assessing the Appropriate Timing of Type 2 diAbetes INtensification (ATTAIN).

Authors:  Edward B Jude; Caroline O'Leary; Melissa Myland; Mark Nixon; Nick Gooch; Alka Shaunik; Elisheva Lew
Journal:  Endocrinol Diabetes Metab       Date:  2019-09-29

6.  Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension.

Authors:  Sean Studer; Michael Hull; Janis Pruett; Caitlin Elliott; Yuen Tsang; William Drake
Journal:  Pulm Ther       Date:  2019-12-19

7.  Low medication adherence is associated with decline in health-related quality of life: results of a longitudinal analysis among older women and men with hypertension.

Authors:  Erin Peacock; Cara Joyce; Leslie S Craig; Zachary Lenane; Elizabeth W Holt; Paul Muntner; Marie Krousel-Wood
Journal:  J Hypertens       Date:  2021-01       Impact factor: 4.776

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.